NeuPath Health (NPTH) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
28 Aug, 2026Executive summary
Achieved 7% year-over-year revenue growth to $23.2 million in Q2 2026, excluding a prior year one-time payment impact, with record patient visits up 6% and adjusted EBITDA of $1.7 million.
Six new physicians joined after the quarter, expanding service offerings and supporting future growth.
Operates 12 regulated medical facilities in Ontario and Alberta, with approximately 160 healthcare professionals and 200,000 annual patient visits.
Financial highlights
Q2 2026 revenue grew 7% year-over-year to $23.2 million, with an 11% CAGR over three years and adjusted EBITDA up 3% to $1.7 million; year-to-date adjusted EBITDA reached $3.2 million.
Capacity utilization improved to 56% from 52% last year.
Professional fees and operational downtime impacted EBITDA but are now resolved.
Gross margin for Q2 2026 was $4.4 million (19.0% of revenue).
Outlook and guidance
Anticipates continued revenue growth from newly onboarded physicians, expanded service offerings, and new locations.
Guelph facility opening delayed to early Q4 2026, with three new physicians joining.
M&A pipeline is active, with at least one transaction targeted for the back half of the year.
Academic affiliation with TMU expected to impact recruitment and growth over a 3–5 year horizon.
Latest events from NeuPath Health
- Strong revenue growth and expanding physician capacity drive value in a fragmented pain care market.NPTH
2026 Bloom Burton & Co. Healthcare Investor Conference - Q2 2024 revenue up 11% year-over-year, gross margin at 20.0%, net debt down 37%.NPTH
Q2 2024 - Q3 2024 revenue and adjusted EBITDA both rose 9% year-over-year, with improved capacity and lower net debt.NPTH
Q3 2024 - Revenue and adjusted EBITDA rose year-over-year, with new growth investments and clinical milestones.NPTH
Q4 2024 - Record revenue and margin growth in Q1 2025, with new financing and leadership for future expansion.NPTH
Q1 2025 - Record revenue and EBITDA growth driven by clinic optimization and new procedure uptake.NPTH
Q2 2025 - Q1 2026 delivered 11% revenue and 15% EBITDA growth, with expansion and new leadership.NPTH
Q1 2026 - Strong revenue and EBITDA growth, expanding network, and robust balance sheet position.NPTH
Investor presentation - Record 2025 revenue and EBITDA growth, with strong outlook for further expansion and margin gains.NPTH
Q4 2025